Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Beijing Biostar Pharmaceuticals Co., Ltd. Class H ( (HK:2563) ).
Beijing Biostar Pharmaceuticals Co., Ltd. announced a corrigendum to a previous board resolution, clarifying changes in its inventory pricing method and financial reporting standards. The company will switch from a first-in-first-out to a weighted average method for inventory pricing to better reflect cost fluctuations and improve decision-making. Additionally, it confirmed the use of both China Accounting Standards for Business Enterprises and Hong Kong Financial Reporting Standards for its financial statements.
More about Beijing Biostar Pharmaceuticals Co., Ltd. Class H
Beijing Biostar Pharmaceuticals Co., Ltd. is a pharmaceutical company based in the People’s Republic of China. It operates in the biopharmaceutical industry, focusing on the development and production of innovative medical products.
Average Trading Volume: 1,495,166
Technical Sentiment Signal: Hold
Learn more about 2563 stock on TipRanks’ Stock Analysis page.